ArticleInternational journal of surgery (London, England)2026
Decellularized vascular matrix material-based TEVG coated with PRP for anti-degradation and anti-inflammation.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Optimization of TX-100/SDS-based decellularized vascular material using ultrasound and chemical treatment: evaluation of structure and biosafety.Organogenesis · 2026Article
- Decellularized porcine vascular grafts: structural integrity and translational potential for allogeneic implantation.Frontiers in bioengineering and biotechnology · 2026Article
- Platelets: the first cellular responders in the foreign body response to blood-contacting biomaterials.Frontiers in immunology · 2026Review
- From biological scaffold to multifunctional bioplatform: research progress and applications of decellularized extracellular matrix.Frontiers in bioengineering and biotechnology · 2026Review
- Is less inflammation always better? Rethinking remodeling in PRP-modified tissue-engineered vascular grafts - Correspondence.International journal of surgery (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVascular regeneration is closely associated with the inflammatory response and the degradation rate of implants. Platelet-rich plasma (PRP) contains various cytokines and proteins, and autologous PRP can be used to treat implants to reduce the inflammatory response.
objectiveTo reduce the immune rejection response and degradation rate of implants in vivo by incorporating different derivatives of PRP.
methodsTissue-engineered vascular grafts (TEVGs) were separately mixed with phosphate-buffered saline (PBS), fibrin (FIB), platelet growth factor (PGF), and a PGF blend to prepare different extracellular matrix (ECM) implants for cell co-culture and subcutaneous transplantation experiments in rats. The cytokines transforming growth factor-beta, interleukin-10, and transforming growth factor-alpha released by macrophages were detected by enzyme-linked immunosorbent assay. Tissue morphology was examined using hematoxylin and eosin (H&E staining), Masson's trichrome staining, and scanning electron microscopy. The impact of TEVGs on macrophages was evaluated through immunofluorescence and Western blotting. Subcutaneous transplantation in rats was assessed using H&E and Masson's staining, along with immunofluorescence staining for CD206 and CD86 to observe cell numbers and the M2/M1 (alternatively activated macrophages/classically activated macrophages) ratio.
resultsPBS, FIB, PGF, and the PGF blend exhibited distinct morphologies under scanning electron microscopy. Both in vitro and in vivo studies demonstrated an increase in the M2/M1 ratio with PGF and PGF-coated groups, improved water absorption capacity, and delayed metabolism of ECM materials in vivo . Additionally, PRP downregulated multiple inflammation-related genes, thereby reducing the inflammatory response.
conclusionPGF and PGF-coated TEVGs reduced the immune rejection response in subcutaneous transplantation and decreased degradation by mitigating collagen loss in the implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.